NuScale's $75K Quarter and $750M Share Sale Underscore Dilution Risk

What happened

NuScale Power reported just $75,000 in quarterly revenue and announced a $750 million share sale, confirming that commercialization remains distant and funding continues to rely on equity rather than customer cash. The company holds $1.9 billion in cash and investments from prior raises, but this new sale will further dilute shareholders, with Class A shares already up to 410.4 million from 318.5 million at year-end 2025. The DeepValue master report rates SMR a WAIT, noting there is still no binding NPM delivery contract and TVA/ENTRA1 discussions remain non-binding pending power purchase agreements. Romania's financing gate is unresolved, with Nuclearelectrica reporting no concrete results from Ministry of Energy discussions, keeping Europe as a non-catalyst. The market increasingly treats SMR as a "show me" story, and this news underscores that cash burn is funded by dilution, not by customer commitments.

Implication

The $750 million share sale is a negative for per-share value but extends NuScale's liquidity runway into 2027, keeping solvency risk low while dilution risk rises. Until a binding PPA or OEM contract is disclosed, revenue will remain minimal and the stock is likely to drift toward the bear-case $7 level, especially if TVA and Romania stall further. Conversely, a definitive off-take agreement would validate the technology and could support a move toward the bull-case $13, but the probability remains low at 25%. The insider selling by Fluor in April and the ongoing dilution signal that even strategic partners are reducing risk, so investors should require a significant margin of safety before entering. We maintain our WAIT rating with an attractive entry below $8 and a trim above $13, pending concrete commercial milestones.

Thesis delta

The news does not alter our WAIT thesis; it reinforces it by adding a large incremental share sale to the existing cash burn. While the balance sheet remains strong with no debt, the path to value is now even more dependent on contract conversion, as continued equity issuance erodes per-share upside. Therefore, we keep the same rating and entry levels but note that dilution risk has increased, justifying a wider margin of safety.